Alexion Pharmaceuticals (ALXN) fired its CEO and chief financial, as it is in the midst of an internal investigation looking into allegations of improper sales practices connected with its top selling drug Soliris. Soliris sales have totaled $2.2 billion in the first three quarters of the year. Alexion also said its 10-Q filling for the third quarter will now be filed in January. An Alexian Board member, David Brennan, is taking over immediately as interim CEO. He is a former CEO at AstraZeneca (AZN) .
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.